The Dermatology Service of the Ramón y Cajal Hospital has launched the study “Definitive Alopecia in cancer patients: epidemiological, clinical and prognostic factors”. This is a research project to determine the possible factors that allow predicting that patients will develop definitive alopecia after having received an oncological treatment based on the analysis of the epidemiological and clinical characteristics and the treatments that have received the patients who Have developed this type of alopecia.
Alopecia is a frequent adverse effect of some chemotherapy drugs; however, it is usually reversible and the patient regains full capillary density around 3-6 months after the end of the oncological treatment that produced it; However, in some cases, this alopecia is not completely or partially reversible.
Definitive alopecia is defined as loss of partial or total capillary density that persists 6 months after the end of the cause that caused it. The cause of this alopecia seems to be direct damage on follicular stem cells.
Alopecia has a great impact on the quality of life in the patients affected by this disease, and in many cases patients are anxious about the possibility of losing their hair when starting an oncological treatment; This anxiety sometimes leads patients to reject such treatments.
However, there are no large series published that allow to analyze in detail the profile of patients at risk for this alopecia or the possible predictive factors of it.
This study is performed in cancer patients clinically diagnosed with definitive alopecia.
Description of the study
The study consists of two visits in consultation separated by 6 months, in which the dermatologist will ask the patient a series of questions about his illness, the treatments he has used since he was diagnosed the disease and the response to each one , Will also be made an anamnesis centered on his problem of alopecia and a clinical exploration directed with obtaining iconography making clinical and dermatoscopic photographs of the scalp in order to assess the degree of alopecia and how it evolves in the time elapsed between the two Visits.
In the case of diagnostic doubt, the complementary examinations that are convenient in the case will be carried out, following the usual clinical practice. Finally, the patient will perform a validated quality of life test, to study the impact that this disease causes in daily life. If it is considered opportune the dermatologist can guide a treatment for alopecia, whose answer will be evaluated in the second visit.
Both the research team and the Hospital will not receive any financial compensation for the study.
Purpose of this research study
The main objective is to describe the epidemiological characteristics, personal history, clinical characteristics, prognosis and therapeutics of a wide range of cancer patients with definitive alopecia, as well as to try to define possible predictive factors for the development of this disease.
Benefits of participating in this study
The patient who enters the study can benefit from the knowledge that is obtained from the same therapeutic prognostic level.
Possible risks of participating in this study
There is no risk to health derived from participation in this study.
Participation and withdrawal of the study
Participation in this study is entirely voluntary. The patient may discontinue his participation in this study at any time, without affecting the medical care he receives.
Contact details for more information
The study physician and / or team members will be available to answer any questions that may arise about the study. For more information, please contact Dr. Ángela Hermosa Gelbard by calling 913368247/913368582 or by sending an email to: email@example.com.